- Philips’ holistic approach to personalized cardiovascular care drives first time right diagnoses and more confident clinical decision support to help improve patient outcomes and reduce costs
- Integrated cardiology software and solutions deliver actionable insights and seamlessly connect people, technologies and care protocols to help inform quickest path to targeted treatment
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced its participation in the 2016 American College of Cardiology’s Annual Scientific Session and Expo (ACC.16), taking place April 2-4, 2016 in Chicago, Ill. The Philips booth (#6054) will feature innovative connected cardiology solutions to help coordinate care delivery, create individualized treatment plans and drive satisfaction among care teams and their patients, to expand quality access to care and help improve patient outcomes with the quickest path to targeted treatment. The company will also feature noted thought leaders participating in “Cardiology Talks” in the Philips booth throughout the event.
Cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year, and is expected to grow to more than 23.6 million by 2030.1 Cardiology is one of the top health technology priorities for Philips, which provides integrated solutions helping clinicians treat cardiovascular disease by speeding detection, diagnosis and treatment, driving more effective recovery and home care, and encouraging prevention and healthy living.
“The expanding profile of cardiac patients creates even more variables in diagnosis and treatment, making the need for innovative connected care solutions and customized treatment plans more crucial than ever,” said Bert van Meurs, CEO Image Guided Therapy (IGT), Philips. “One emerging area making a huge impact in interventional cardiovascular care is Image Guided Therapy. Philips is developing technology that helps clinicians decide, guide and confirm the right therapy for the right patient at the point of care. Working together with cardiology leaders in clinical studies and trials to realize this vision, we can help save and improve lives, and reduce the total cost of care by making therapy more efficient, more appropriate and more personal.”
The Philips booth will showcase examples of its advanced cardiology and connected health solutions with a focus on prevention, diagnosis and treatment, and will host a range of global thought leaders in the cardiology space, including:
- Cardiology Talks—A series of conversations with thought leaders discussing key findings, trends and ideas throughout ACC.16, featuring:
- Charles Whitney, MD, family practitioner/owner, Revolutionary Health Services in Washington Crossing, Penn., will lead two sessions: “Oral Bacteremia: The science connecting the oral cavity to ASVD” (Saturday, April 2nd from 10:15-10:40am CT) and “Bridging the Oral-Systemic Gap: The ease and values of implementing oral-systemic care into a busy cardiology practice” (Saturday, April 2nd from 12:30-12:55pm)o
- Sukhjinder Nijjer, MBChB, PhD, specialist registrar in cardiology and clinical research fellow, Imperial College London, will discuss “Are you stenting the correct stenosis? Using iFR Scout to move from vessel level assessment to lesion level assessment”(Saturday, April 2nd from 11:00-11:25am and Sunday, April 3rd from 12:30-12:55pm)
- Wendy Tsang, MD, Assistant Professor, University of Toronto; Cardiologist at Toronto General Hospital, University Health Network, will explore “Echocardiography in 2016: How does HeartModel change practice?” (Sunday, April 3rd from 1:30-1:55pm)
- Jeroen Brouwer, director of business development, Personal Health Solutions for Philips, will discuss “The importance of lifestyle change programs and prevention for consumers” (Saturday, April 2nd, from 4:00pm–4:25pm)
- Innovative cardiology technologies—The Philips booth will showcase a portfolio of integrated cardiovascular solutions designed to deliver cost effective, collaborative cardiovascular care, including:
Additionally, today Philips announced an update on three prospective clinical studies to assess the safety of deferring cardiovascular interventions using Philips Volcano’s proprietary iFR (instant wave-Free Ratio) pressure measurement technology versus conventional FFR (Fractional Flow Reserve) measurements. More than 5,000 patients have been enrolled in the studies, with one-year results expected in 2017.
For more information on Philips’ integrated cardiology solutions and presence at ACC, visit https://www.usa.philips.com/healthcare/about/events-calendar/acc-2016 and follow the #ACC16 conversation via @PhilipsLiveFrom and @PhilipsHealth.
1 2015 Heart Disease and Stroke Statistics Update, American Heart Association, Centers for Disease Control and Prevention, the National Institutes of Health, et al.